Beyond Tanimoto: a learned bioactivity similarity index enhances ligand discovery

Structural similarity metrics such as the Tanimoto coefficient (TC) miss many functionally related compounds-indeed, 60% of similarly bioactive ligand pairs in the ChEMBL database show TC < 0.30, revealing a major blind spot that constrains ligand-based discovery. Our motivation is to overcome this blind spot and enable the recovery of structurally different yet functionally equivalent chemotypes that structure-based similarity fails to detect. Here, we introduce the bioactivity similarity index (BSI), a machine learning model that estimates the probability that two molecules bind the same or related protein receptors. Trained under leave-one-protein-out (LOPO) across Pfam-defined protein groups on dissimilar pairs, BSI not only outperforms TC but also surpasses modern molecular embedding baselines (ChemBERTa and contrastive language-molecule pre-training (CLAMP), using cosine similarity) across protein families. We further develop a cross-family model (BSI-Large) that, while slightly below group-specific models, generalizes better and can be fine-tuned with less data, consistently improving over models trained from scratch. In retrospective validation on new ChEMBL v35 data, BSI achieves strong early-retrieval performance (top 2% enrichment factor, EF<sub>2%</sub>), with group-specific models delivering the best enrichment, and BSI-Large remaining competitive. In a realistic virtual screening-like scenario against the target gene ADRA2B, the mean rank of the next active, given a known active, improves from 45.2 (TC) to 3.9 (BSI), with 54.9 for ChemBERTa and 28.6 for CLAMP. Altogether, BSI complements, rather than replaces, structure-based similarity and embedding-based comparisons, extending hit finding to remote chemotypes that are structurally dissimilar yet functionally equivalent. The code is available at https://github.com/gschottlender/bioactivity-similarity-index.

Authors

Institutions

Publication Details

Journal
Frontiers in Bioinformatics
Published
2025-11-28
DOI
https://doi.org/10.3389/fbinf.2025.1695353
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Beyond Tanimoto: a learned bioactivity similarity index enhances ligand discovery

Juan Manuel Prieto, Gustavo Schottlender, Marcelo A. Martí, Darío Fernández Do Porto
Frontiers in Bioinformatics
Computational Drug Discovery Methods
article

Beyond Tanimoto: a learned bioactivity similarity index enhances ligand discovery

Juan Manuel Prieto, Gustavo Schottlender, Marcelo A. Martí, Darío Fernández Do Porto
article en

Abstract

Structural similarity metrics such as the Tanimoto coefficient (TC) miss many functionally related compounds-indeed, 60% of similarly bioactive ligand pairs in the ChEMBL database show TC < 0.30, revealing a major blind spot that constrains ligand-based discovery. Our motivation is to overcome this blind spot and enable the recovery of structurally different yet functionally equivalent chemotypes that structure-based similarity fails to detect. Here, we introduce the bioactivity similarity index (BSI), a machine learning model that estimates the probability that two molecules bind the same or related protein receptors. Trained under leave-one-protein-out (LOPO) across Pfam-defined protein groups on dissimilar pairs, BSI not only outperforms TC but also surpasses modern molecular embedding baselines (ChemBERTa and contrastive language-molecule pre-training (CLAMP), using cosine similarity) across protein families. We further develop a cross-family model (BSI-Large) that, while slightly below group-specific models, generalizes better and can be fine-tuned with less data, consistently improving over models trained from scratch. In retrospective validation on new ChEMBL v35 data, BSI achieves strong early-retrieval performance (top 2% enrichment factor, EF<sub>2%</sub>), with group-specific models delivering the best enrichment, and BSI-Large remaining competitive. In a realistic virtual screening-like scenario against the target gene ADRA2B, the mean rank of the next active, given a known active, improves from 45.2 (TC) to 3.9 (BSI), with 54.9 for ChemBERTa and 28.6 for CLAMP. Altogether, BSI complements, rather than replaces, structure-based similarity and embedding-based comparisons, extending hit finding to remote chemotypes that are structurally dissimilar yet functionally equivalent. The code is available at https://github.com/gschottlender/bioactivity-similarity-index.

Frontiers in BioinformaticsVol. 5
Universidad de Buenos Aires (AR), Bio-Medical Science (South Korea) (KR), Fundación Ciencias Exactas y Naturales (AR)
Consejo Nacional de Investigaciones Científicas y Técnicas
Openalex Percentile: Top 63%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.